Peptide and Oligonucleotide CDMO Market Size & Growth Forecast 2027–2036, By Segments (Product, Service Type, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Peptide and Oligonucleotide CDMO Market size was valued at USD 3.5 billion in 2026 and is anticipated to grow at a 12.26% CAGR from 2027 to 2036, exceeding USD 11.13 billion by 2036. The industry revenue for 2027 is calculated at USD 3.86 billion.
Get more details on this report
Request Free Sample ReportPeptide and Oligonucleotide CDMO Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with 38.55% share due to its mature outsourcing ecosystem, advanced manufacturing infrastructure, and strong reliance on contract partners for complex peptide and oligonucleotide production.
- Asia Pacific is expanding at 14% CAGR driven by rising outsourcing demand, expanding specialized manufacturing capacity, and increasing adoption by global drug developers seeking flexible and cost-efficient scale-up solutions.
Segment Momentum
- Peptides accounted for 65.46% of the market in 2026, supported by an established outsourcing base and strong demand for reliable scale-up, synthesis consistency, and quality-controlled manufacturing services.
- Contract Development is the fastest-growing service type as sponsors increasingly outsource process design, optimization, and analytical development earlier to reduce technical risk and improve manufacturing readiness.
Market Expansion Drivers
- Increasing demand for targeted biologics and nucleic acid therapeutics boosting CDMO outsourcing activities.
- Advancements in peptide synthesis and oligonucleotide manufacturing improving scalability of complex therapeutics.
- Growing personalized medicine adoption driving need for customized peptide and oligonucleotide production services.
Leading Market Participants
- Leading players in the peptide and oligonucleotide CDMO market include Lonza Group AG (Switzerland), Thermo Fisher Scientific Inc. (United States), WuXi STA Pharmaceutical Co., Ltd. (China), Bachem Holding AG (Switzerland), PolyPeptide Group AG (Switzerland), CordenPharma International (Switzerland), Curia Global Inc. (United States), EUROAPI S.A. (France), Aurigene Pharmaceutical Services Ltd. (India), Asahi Kasei Corporation (Japan).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 3.5 billion
- 2027 Estimated Market Size: USD 3.86 billion.
- Projected Market Size: USD 11.13 billion by 2036
- Growth Forecast: 12.26% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Peptides (Product) | Contract Manufacturing (Service Type) | Biopharmaceutical Companies (End Use)
- Emerging Opportunity Segment: Oligonucleotides (Product) | Contract Development (Service Type) | Biopharmaceutical Companies (End Use)
Market Growth Drivers and Industry Trends
Increasing demand for targeted biologics and nucleic acid therapeutics boosting CDMO outsourcing activities
The growing development of targeted biologics and nucleic acid-based medicines is increasing the complexity of pharmaceutical manufacturing, supporting the peptide and oligonucleotide CDMO market as developers seek specialized external production capabilities. Peptides and oligonucleotides require sophisticated synthesis, purification, analytical testing, and process development expertise that may be difficult to establish internally for every pharmaceutical developer. Outsourcing to specialized contract development and manufacturing organizations enables drug developers to access dedicated manufacturing infrastructure and technical capabilities while focusing internal resources on research and clinical development. The increasing pipeline of complex therapeutics is therefore creating demand for specialized outsourcing services across development and production stages.
Advancements in peptide synthesis and oligonucleotide manufacturing improving scalability of complex therapeutics
Technological improvements in synthesis, purification, process control, and analytical methods are making complex therapeutic production more efficient, contributing to the peptide and oligonucleotide CDMO market. Advances in manufacturing processes can improve consistency and enable CDMOs to handle increasingly sophisticated molecules while addressing challenges associated with purity, yield, and process reproducibility. Enhanced production platforms also support the transition of promising therapeutic candidates from development into larger-scale manufacturing environments. As pharmaceutical developers require dependable processes for increasingly complex molecules, specialized CDMOs are strengthening their capabilities in synthesis and manufacturing technologies.
Growing personalized medicine adoption driving need for customized peptide and oligonucleotide production services
The shift toward personalized medicine is increasing demand for flexible manufacturing services capable of producing therapies tailored to specific patient populations or molecular targets. The peptide and oligonucleotide CDMO market will benefit as pharmaceutical developers require customized production approaches for specialized therapeutic candidates with distinct formulation and manufacturing requirements. Personalized treatment strategies can involve smaller or more differentiated product requirements, making adaptable development and manufacturing capabilities particularly valuable. CDMOs with specialized expertise can support customized synthesis, analytical characterization, process development, and production activities while helping developers manage the technical requirements associated with individualized therapeutic approaches.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing demand for targeted biologics and nucleic acid therapeutics boosting CDMO outsourcing activities | 2.10% | High | North America, Europe | High | Near Term |
| Advancements in peptide synthesis and oligonucleotide manufacturing improving scalability of complex therapeutics | 1.90% | Moderate | North America, Asia Pacific | High | Mid Term |
| Growing personalized medicine adoption driving need for customized peptide and oligonucleotide production services | 1.60% | High | Europe, Asia Pacific | Emerging | Long Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
In the peptide and oligonucleotide CDMO market, North America accounted for a 38.55% share in 2026, reflecting its strong pharmaceutical and biotechnology ecosystem, advanced drug development capabilities, and established outsourcing infrastructure. Growing development of peptide- and nucleic acid-based therapeutics is increasing demand for specialized manufacturing services covering process development, synthesis, analytical testing, and scale-up activities. The region's concentration of biotechnology research and clinical development programs provides CDMOs with a broad customer base seeking flexible and technically sophisticated manufacturing support. Moreover, increasing complexity in drug development and the need to access specialized production capabilities are encouraging pharmaceutical and biotechnology companies to outsource selected activities, supporting continued demand for integrated CDMO services.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing regional market, driven by expanding pharmaceutical manufacturing capacity, increasing biotechnology investment, and rising demand for specialized production services. The development of peptide and oligonucleotide therapeutics is encouraging manufacturers in the region to strengthen capabilities in synthesis, purification, analytical development, and commercial-scale production. Growing efforts to establish advanced biopharmaceutical manufacturing infrastructure are also improving the region's attractiveness for outsourced development and production. In addition, cost-conscious outsourcing strategies, expanding domestic drug development activity, and improvements in regulatory and quality capabilities are supporting greater participation in complex pharmaceutical manufacturing programs and strengthening the region's growth trajectory.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Quality-Focused Development ServicesGermany emphasizes peptide and oligonucleotide CDMO services that combine manufacturing precision with rigorous quality standards. Companies continue strengthening process development, analytical testing, and compliant production to support innovative drug pipelines.
France 🇫🇷
Clinical Manufacturing SupportFrance prioritizes peptide and oligonucleotide CDMO services that facilitate clinical development and specialized therapeutic manufacturing. Providers focus on scalable production processes, regulatory readiness, and collaborative development models that accelerate pharmaceutical programs.
Italy 🇮🇹
Flexible Production CapabilitiesItaly continues enhancing peptide and oligonucleotide CDMO services through flexible manufacturing and customized development support. Italian organizations invest in process optimization, quality assurance, and specialized production technologies that address diverse therapeutic development needs.
Japan 🇯🇵
Specialized Process ExcellenceJapan continues advancing peptide and oligonucleotide CDMO capabilities through specialized manufacturing technologies and quality-driven operations. Japanese service providers focus on reliable production workflows that support complex therapeutic molecules from development through commercial supply.
South Korea 🇰🇷
Biopharmaceutical Capacity ExpansionSouth Korea is strengthening peptide and oligonucleotide CDMO capabilities to support domestic innovation and international pharmaceutical partnerships. Companies are expanding manufacturing infrastructure, technical expertise, and quality systems to meet increasingly sophisticated customer requirements.
United States 🇺🇸
Complex Therapeutics ManufacturingThe U.S. peptide and oligonucleotide CDMO market is expanding manufacturing capabilities for advanced therapeutics through process optimization and scalable production. Service providers invest in analytical expertise, regulatory compliance, and flexible capacity to support pharmaceutical development programs.
Segment Leadership and Growth Trends
Peptide and Oligonucleotide CDMO Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Peptides (Largest Segment) vs Oligonucleotides (Fastest-Growing Segment)
Peptides held the largest share of the peptide and oligonucleotide CDMO market at 65.46% in 2026, supported by established demand for peptide-based therapeutics and the increasing need for specialized manufacturing capabilities. Peptide production requires controlled processes and technical expertise, encouraging pharmaceutical and biotechnology developers to rely on specialized contract partners for scalable manufacturing. Growing development activity involving peptide-based treatments and the need to access external production capabilities are sustaining the segment's leading position.
Oligonucleotides represent the fastest-growing product segment, supported by expanding interest in nucleic-acid-based therapeutic approaches and the specialized manufacturing requirements associated with these products. Their production involves complex synthesis, purification, and quality-control processes, creating opportunities for CDMOs with dedicated technical capabilities. As drug developers increasingly pursue advanced therapeutic modalities, demand for external expertise and manufacturing infrastructure for oligonucleotides is strengthening.
Service Type Segment Analysis: Contract Manufacturing (Largest Segment) vs Contract Development (Fastest-Growing Segment)
Contract manufacturing represented the largest share of the peptide and oligonucleotide CDMO market in 2026, reflecting the continued need among drug developers for external production capacity and specialized manufacturing expertise. Outsourcing manufacturing enables organizations to access established production capabilities while focusing internal resources on research, clinical development, and commercialization activities. Increasing complexity in peptide and oligonucleotide production is further reinforcing reliance on specialized contract manufacturers.
Contract development is the fastest-growing service type, driven by the increasing need for specialized expertise during the early stages of product development. Developers require support in optimizing processes, improving scalability, and establishing reproducible manufacturing approaches before transitioning to commercial production. The growing complexity of peptide and oligonucleotide development is therefore encouraging greater use of external development capabilities alongside traditional manufacturing outsourcing.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Peptides, Oligonucleotides | Peptides | Oligonucleotides |
| Service Type | Contract Development, Contract Manufacturing | Contract Manufacturing | Contract Development |
| End Use | Pharmaceutical Companies, Biopharmaceutical Companies, Others | Biopharmaceutical Companies | Biopharmaceutical Companies |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Key companies in the peptide and oligonucleotide CDMO market:
1. Lonza Group AG (Switzerland)
2. Thermo Fisher Scientific Inc. (United States)
3. WuXi STA Pharmaceutical Co. Ltd. (China)
4. Bachem Holding AG (Switzerland)
5. PolyPeptide Group AG (Switzerland)
6. CordenPharma International (Switzerland)
7. Curia Global Inc. (United States)
8. EUROAPI S.A. (France)
9. Aurigene Pharmaceutical Services Ltd. (India)
10. Asahi Kasei Corporation (Japan)
The peptide and oligonucleotide CDMO market is evolving through increasing demand for specialized outsourcing services that support complex drug development and scalable manufacturing processes. Service providers are enhancing production flexibility, analytical capabilities, and regulatory compliance systems to meet growing biopharmaceutical requirements. Technological improvements in synthesis efficiency and precision manufacturing are also accelerating growth in the peptide and oligonucleotide CDMO market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Lonza Group AG (Switzerland) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| WuXi STA Pharmaceutical Co. Ltd. (China) | |||||||
| Bachem Holding AG (Switzerland) | |||||||
| PolyPeptide Group AG (Switzerland) | |||||||
| CordenPharma International (Switzerland) | |||||||
| Curia Global Inc. (United States) | |||||||
| EUROAPI S.A. (France) | |||||||
| Aurigene Pharmaceutical Services Ltd. (India) | |||||||
| Asahi Kasei Corporation (Japan). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Samsung Biologics | Apr-25 | Samsung Biologics commenced operations at its fifth production plant, adding 180,000 liters of capacity and launching a dedicated facility for antibody-drug conjugates (ADCs). The facility expansion is bolstered by a USD 1.4 billion multi-year CDMO contract, significantly strengthening the company’s manufacturing footprint and bioprocessing capabilities for complex drug modalities. |
| CordenPharma | Jul-24 | CordenPharma announced a significant expansion of its global peptide platform with a planned investment of EUR 900 million (approximately USD 1 billion). The initiative involves both site expansions and new facility constructions across Colorado, U.S., and Europe, aimed at scaling capacity to meet the surging demand for GLP-1 peptide therapeutics. |
| EUROAPI | Nov-23 | EUROAPI completed the acquisition of BianoGMP, an oligonucleotide CDMO specialist. This strategic integration enhances EUROAPI's service portfolio for the high-growth oligonucleotide market, enabling the company to support clients throughout the entire development continuum, from early-stage research to commercial-scale manufacturing. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Peptide and Oligonucleotide CDMO Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Development Stage | Preclinical Development, Clinical Development, Commercial Manufacturing |
| Therapeutic Area | Oncology, Metabolic & Endocrine Disorders, Cardiovascular & Other Chronic Diseases, Infectious & Immune Disorders |
| Manufacturing Scale | Laboratory & Preclinical Scale, Clinical Scale, Commercial Scale |
Peptide and Oligonucleotide CDMO Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Outsourcing Demand Assessment |
|
| Technology Platform Adoption Landscape |
|
| Regional Manufacturing Hub Evaluation |
|
Need a different cut of the data?
Request Custom ResearchHow much is the peptide and oligonucleotide CDMO market worth?
How is the peptide and oligonucleotide CDMO industry projected to perform over the next decade?
Why are drug developers expanding outsourcing in the peptide and oligonucleotide CDMO market?
How is personalized medicine reshaping demand for peptide and oligonucleotide CDMO services?
Which product segment holds the largest share of the peptide and oligonucleotide CDMO market?
What is the fastest-growing service segment in the peptide and oligonucleotide CDMO market?
Why does North America hold the largest share in the peptide and oligonucleotide CDMO market?
What is fueling the fastest growth of peptide and oligonucleotide CDMO services in Asia Pacific?
What are the key competitors in the peptide and oligonucleotide CDMO landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization